Related Experiment Video
Updated: Apr 13, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Emerging therapies in bone metastasis
Lise Clément-Demange1, Philippe Clézardin1
1INSERM, UMR 1033, Lyon F-69372, France; Université Lyon-1, Villeurbanne F-69622, France.
Abstract:
Skeletal lesions contribute substantially to morbidity and mortality in patients with cancer. Emerging treatments for metastatic bone disease have arisen from our understanding of the biology of bone metastases. Tumour cells alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. Drugs that inhibit osteoclast-mediated bone resorption (denosumab, bisphosphonates) are the standard of care for patients with skeletal metastases. In this review, we describe the progress and future directions of novel bone-targeted therapies that not only focus on osteoclasts, but also on osteoblasts and the bone microenvironment.
Insights
Cancer patients with bone metastases face significant risks. New therapies target bone destruction by focusing on osteoclasts, osteoblasts, and the bone microenvironment for improved outcomes.
Area of Science:
- Oncology
- Orthopedics
- Pharmacology
Background:
- Skeletal lesions are a major cause of illness and death in cancer patients.
- Tumor cells disrupt bone remodeling by altering osteoclast and osteoblast activity, leading to bone destruction.
- Current treatments focus on inhibiting osteoclast-mediated bone resorption.
Purpose of the Study:
- To review the progress and future directions of novel bone-targeted therapies for metastatic bone disease.
- To explore therapies that target not only osteoclasts but also osteoblasts and the bone microenvironment.
Main Methods:
- Literature review of recent advancements in bone metastasis research.
- Analysis of emerging therapeutic strategies targeting bone cells and the bone microenvironment.
Main Results:
- Established treatments like denosumab and bisphosphonates are effective against osteoclast activity.
- Emerging therapies show promise in modulating both bone resorption and formation.
- Targeting the bone microenvironment offers new avenues for treatment.
Conclusions:
- Novel bone-targeted therapies are expanding treatment options for metastatic bone disease.
- A comprehensive approach involving osteoclasts, osteoblasts, and the bone microenvironment is crucial.
- Future research should focus on integrating these novel strategies for better patient outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Immunotherapy

